{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:39:04Z","timestamp":1782963544067,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,24]]},"DOI":"10.7759\/cureus.76315","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T15:36:14Z","timestamp":1735054574000},"source":"Crossref","is-referenced-by-count":1,"title":["A Prospective, Observational, Open-Label, Non-comparative, Multi-center Study for the Evaluation of Efficacy and Safety of Levonadifloxacin (Intravenous and Oral) in Patients With Community-Acquired Bacterial Pneumonia"],"prefix":"10.7759","author":[{"given":"Abhijit","family":"Telkhade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chintan","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul Kumar","family":"Rathode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhanu","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrikant","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji","family":"More","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhangi","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz090","article-title":"Efficacy and safety of intravenous-to-oral Lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) trial","volume":"69","author":"File TM","year":"2019","unstructured":"File TM, Goldberg L, Das A, et al.. Efficacy and safety of intravenous-to-oral Lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) trial. Clin Infect Dis. 2019, 69:1856-67. 10.1093\/cid\/ciz090","journal-title":"Clin Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets R","year":"2019","unstructured":"Stets R, Popescu M, Gonong JR, et al.. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019, 380:517-27. 10.1056\/NEJMoa1800201","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/lungindia.lungindia_38_19","article-title":"Management of community-acquired bacterial pneumonia in adults: Limitations of current antibiotics and future therapies","volume":"36","author":"Nayar S","year":"2019","unstructured":"Nayar S, Hasan A, Waghray P, Ramananthan S, Ahdal J, Jain R. Management of community-acquired bacterial pneumonia in adults: Limitations of current antibiotics and future therapies. Lung India. 2019, 36:525-33. 10.4103\/lungindia.lungindia_38_19","journal-title":"Lung India"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00017-7","article-title":"Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL)","volume":"16","author":"Barrera CM","year":"2016","unstructured":"Barrera CM, Mykietiuk A, Metev H, et al.. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL). Lancet Infect Dis. 2016, 16:421-30. 10.1016\/S1473-3099(16)00017-7","journal-title":"Lancet Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200709060-00007","article-title":"Management of community-acquired pneumonia in children","volume":"9","author":"Chetty K","year":"2007","unstructured":"Chetty K, Thomson AH. Management of community-acquired pneumonia in children. Paediatr Drugs. 2007, 9:401-11. 10.2165\/00148581-200709060-00007","journal-title":"Paediatr Drugs"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1312885","article-title":"Community-acquired pneumonia","volume":"371","author":"Musher DM","year":"2014","unstructured":"Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med. 2014, 371:1619-28. 10.1056\/NEJMra1312885","journal-title":"N Engl J Med"},{"key":"ref7","article-title":"The IDSA\/ATS consensus guidelines on the management of CAP in adults","volume":"4","author":"Piffer F","year":"2007","unstructured":"Piffer F, Tardini F, Cosentini R. The IDSA\/ATS consensus guidelines on the management of CAP in adults. Breathe. 2007, 4:110-5.","journal-title":"Breathe"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.121434","article-title":"BTS guidelines for the management of community acquired pneumonia in adults: update 2009","volume":"64 Suppl 3","author":"Lim WS","year":"2009","unstructured":"Lim WS, Baudouin SV, George RC, et al.. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009, 64 Suppl 3:iii1-55. 10.1136\/thx.2009.121434","journal-title":"Thorax"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4103\/0970-2113.99248","article-title":"Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: joint ICS\/NCCP(I) recommendations","volume":"29","author":"Gupta D","year":"2012","unstructured":"Gupta D, Agarwal R, Aggarwal AN, et al.. Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: joint ICS\/NCCP(I) recommendations. Lung India. 2012, 29:S27-62. 10.4103\/0970-2113.99248","journal-title":"Lung India"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/slct.201903380","article-title":"Synthesis and pharmacological evaluation of some amide functionalized 1H\u2010benzo[d]imidazole\u20102\u2010thiol derivatives as antimicrobial agents","volume":"5","author":"Singu PS","year":"2020","unstructured":"Singu PS, Kanugala S, Dhawale SA, Kumar CG, Ravindra M. Synthesis and pharmacological evaluation of some amide functionalized 1H\u2010benzo[d]imidazole\u20102\u2010thiol derivatives as antimicrobial agents. ChemistrySelect. 2020, 5:117-23. 10.1002\/slct.201903380","journal-title":"ChemistrySelect"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2013.11.2710","article-title":"The changing microbiologic epidemiology of community-acquired pneumonia","volume":"125","author":"Aliberti S","year":"2013","unstructured":"Aliberti S, Kaye KS. The changing microbiologic epidemiology of community-acquired pneumonia. Postgrad Med. 2013, 125:31-42. 10.3810\/pgm.2013.11.2710","journal-title":"Postgrad Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03838.x","article-title":"Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials","volume":"19","author":"Skalsky K","year":"2013","unstructured":"Skalsky K, Yahav D, Lador A, Eliakim-Raz N, Leibovici L, Paul M. Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials. Clin Microbiol Infect. 2013, 19:370-8. 10.1111\/j.1469-0691.2012.03838.x","journal-title":"Clin Microbiol Infect"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958002-00002","article-title":"Mode of action of fluoroquinolones","volume":"58 Suppl 2","author":"Hooper DC","year":"1999","unstructured":"Hooper DC. Mode of action of fluoroquinolones. Drugs. 1999, 58 Suppl 2:6-10. 10.2165\/00003495-199958002-00002","journal-title":"Drugs"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(03)00671-6","article-title":"Fluoroquinolones, tuberculosis, and resistance","volume":"3","author":"Ginsburg AS","year":"2003","unstructured":"Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis. 2003, 3:432-42. 10.1016\/s1473-3099(03)00671-6","journal-title":"Lancet Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S229882","article-title":"Levonadifloxacin, a novel broad-spectrum anti-MRSA benzoquinolizine quinolone agent: review of current evidence","volume":"13","author":"Bhagwat SS","year":"2019","unstructured":"Bhagwat SS, Nandanwar M, Kansagara A, et al.. Levonadifloxacin, a novel broad-spectrum anti-MRSA benzoquinolizine quinolone agent: review of current evidence. Drug Des Devel Ther. 2019, 13:4351-65. 10.2147\/DDDT.S229882","journal-title":"Drug Des Devel Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmmb.2022.11.005","article-title":"India-discovered levonadifloxacin & alalevonadifloxacin: a review on susceptibility testing methods, CLSI quality control and breakpoints along with a brief account of their emerging therapeutic profile as a novel standard-of-care","volume":"41","author":"Veeraraghavan B","year":"2023","unstructured":"Veeraraghavan B, Bakthavatchalam YD, Manesh A, et al.. India-discovered levonadifloxacin & alalevonadifloxacin: a review on susceptibility testing methods, CLSI quality control and breakpoints along with a brief account of their emerging therapeutic profile as a novel standard-of-care. Indian J Med Microbiol. 2023, 41:71-80. 10.1016\/j.ijmmb.2022.11.005","journal-title":"Indian J Med Microbiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00641-06","article-title":"The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase","volume":"50","author":"Bhagwat SS","year":"2006","unstructured":"Bhagwat SS, Mundkur LA, Gupte SV, Patel MV, Khorakiwala HF. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase. Antimicrob Agents Chemother. 2006, 50:3568-79. 10.1128\/AAC.00641-06","journal-title":"Antimicrob Agents Chemother"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.001102","article-title":"Levonadifloxacin (WCK 771) exerts potent intracellular activity against Staphylococcus aureus in THP-1 monocytes at clinically relevant concentrations","volume":"68","author":"Dubois J","year":"2019","unstructured":"Dubois J, Dubois M. Levonadifloxacin (WCK 771) exerts potent intracellular activity against Staphylococcus aureus in THP-1 monocytes at clinically relevant concentrations. J Med Microbiol. 2019, 68:1716-22. 10.1099\/jmm.0.001102","journal-title":"J Med Microbiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2021.128432","article-title":"Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection","volume":"54","author":"Bhawsar S","year":"2021","unstructured":"Bhawsar S, Kale R, Deshpande P, Yeole R, Bhagwat S, Patel M. Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection. Bioorg Med Chem Lett. 2021, 54:128432. 10.1016\/j.bmcl.2021.128432","journal-title":"Bioorg Med Chem Lett"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02297-17","article-title":"Intrapulmonary pharmacokinetics of levonadifloxacin following oral administration of alalevonadifloxacin to healthy adult subjects","volume":"62","author":"Rodvold KA","year":"2018","unstructured":"Rodvold KA, Gotfried MH, Chugh R, Gupta M, Yeole R, Patel A, Bhatia A. Intrapulmonary pharmacokinetics of levonadifloxacin following oral administration of alalevonadifloxacin to healthy adult subjects. Antimicrob Agents Chemother. 2018, 62:e02297-17. 10.1128\/AAC.02297-17","journal-title":"Antimicrob Agents Chemother"},{"key":"ref21","unstructured":"WMA Declaration of Helsinki\u2014Ethical Principles for Medical Research Involving Human Subjects. (2023). Accessed. July 12, 2023: https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki\/."},{"key":"ref22","unstructured":"ICH International Council for Harmonisation. Efficacy Guidelines. (2023). Accessed. July 12, 2023: https:\/\/www.ich.org\/page\/efficacy-guidelines."},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002109.pub4","article-title":"Antibiotics for community-acquired pneumonia in adult outpatients","volume":"2014","author":"Pakhale S","year":"2014","unstructured":"Pakhale S, Mulpuru S, Verheij TJ, Kochen MM, Rohde GG, Bjerre LM. Antibiotics for community-acquired pneumonia in adult outpatients. Cochrane Database Syst Rev. 2014, 2014:CD002109. 10.1002\/14651858.CD002109.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.9.3338-3342.2004","article-title":"In vitro activity of the new quinolone WCK 771 against staphylococci","volume":"48","author":"Jacobs MR","year":"2004","unstructured":"Jacobs MR, Bajaksouzian S, Windau A, et al.. In vitro activity of the new quinolone WCK 771 against staphylococci. Antimicrob Agents Chemother. 2004, 48:3338-42. 10.1128\/AAC.48.9.3338-3342.2004","journal-title":"Antimicrob Agents Chemother"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01348-18","article-title":"In vitro activities of the benzoquinolizine fluoroquinolone levonadifloxacin (WCK 771) and other antimicrobial agents against mycoplasmas and ureaplasmas in humans, including isolates with defined resistance mechanisms","volume":"62","author":"Xue G","year":"2018","unstructured":"Xue G, Crabb DM, Xiao L, Liu Y, Waites KB. In vitro activities of the benzoquinolizine fluoroquinolone levonadifloxacin (WCK 771) and other antimicrobial agents against mycoplasmas and ureaplasmas in humans, including isolates with defined resistance mechanisms. Antimicrob Agents Chemother. 2018, 62:10.1128\/AAC.01348-18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01048-19","article-title":"In vitro activity of levonadifloxacin (WCK 771) against Chlamydia pneumoniae","volume":"63","author":"Kohlhoff S","year":"2019","unstructured":"Kohlhoff S, Huerta N, Hammerschlag MR. In vitro activity of levonadifloxacin (WCK 771) against Chlamydia pneumoniae. Antimicrob Agents Chemother. 2019, 63:e01048-19. 10.1128\/AAC.01048-19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00084-20","article-title":"Levonadifloxacin, a novel benzoquinolizine fluoroquinolone, modulates lipopolysaccharide-induced inflammatory responses in human whole-blood assay and murine acute lung injury model","volume":"64","author":"Patel A","year":"2020","unstructured":"Patel A, Sangle GV, Trivedi J, et al.. Levonadifloxacin, a novel benzoquinolizine fluoroquinolone, modulates lipopolysaccharide-induced inflammatory responses in human whole-blood assay and murine acute lung injury model. Antimicrob Agents Chemother. 2020, 64:10.1128\/AAC.00084-20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12594","article-title":"Electrocardiographic effects of a supratherapeutic dose of WCK 2349, a benzoquinolizine fluoroquinolone","volume":"12","author":"Mason JW","year":"2018","unstructured":"Mason JW, Chugh R, Patel A, Gutte R, Bhatia A. Electrocardiographic effects of a supratherapeutic dose of WCK 2349, a benzoquinolizine fluoroquinolone. Clin Transl Sci. 2018, 12:47-52. 10.1111\/cts.12594","journal-title":"Clin Transl Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/224006-a-prospective-observational-open-label-non-comparative-multi-center-study-for-the-evaluation-of-efficacy-and-safety-of-levonadifloxacin-intravenous-and-oral-in-patients-with-community-acquired-bacterial-pneumonia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T15:36:17Z","timestamp":1735054577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/224006-a-prospective-observational-open-label-non-comparative-multi-center-study-for-the-evaluation-of-efficacy-and-safety-of-levonadifloxacin-intravenous-and-oral-in-patients-with-community-acquired-bacterial-pneumonia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.76315","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,24]]}}}